“…It was later discovered that H 3 Rs do not only control histamine release but also, functioning as heteroreceptors, modulate the other neurotransmitter systems, e.g., the cholinergic, , dopaminergic, noradrenergic, , and serotoninergic systems, in both the central and peripheral nervous systems. H 3 R antagonists/inverse agonists demonstrated diverse pharmacological effects in preclinical and clinical studies, highlighting the importance of various central nervous system (CNS)-related therapeutic applications, including Parkinson’s disease and Alzheimer’s disease (AD), narcolepsy, obesity, dementia, epilepsy, schizophrenia, and attention deficit hyperactivity disorder (ADHD) . Recently, many other CNS-related disorders have also been suggested as candidates for treatment by H 3 R antagonist/inverse agonist ligands: Tourette syndrome, Prader–Willi syndrome, depression, or autism …”